Dr. C.K.Krishnan Nair is at present Dean of Research, Pushpagiri Institute of Medical Science & Research Centre and Professor of Biochemistry in MACFAST and also an adjunct faculty at MG University. Prior to his superannuation, he was in Bhabha Atomic Research Centre as Scientific Officer (H), Head, Radiation Biochemistry Section. He obtained MSc and PhD from University of Mumbai. He is a Fellow of the Maharashtra Academy of Sciences, Fellow of Society of Bioscience, Fellow of Indian Society for Radiation Biology and Member of National Academy of Sciences, India. His fields of specialization include Molecular Biology, Biotechnology, Biochemistry, Cellular Stress Response, Radiation Biology, Radiomodifiers in Radiotherapy, Radiation Protection. Nanotehnology, Environmental pollution and Genotoxicity. Dr Nair’s expertise is particularly in DNA technology, analysis of DNA damage and repair, gene expression, gene cloning, DNA sequencing and nanocience for tumor control. He is currently Associate Editor of Journal of Radiation Research, and International Journal of Plant Biology, also Member of the Editorial Board for International Journal of Low Dose Radiation, International Journal of Plant Science Research,Journal of Clinical Medicine and Research, Indian Journal of Zoology and Cell and Chromosome Research and a referee of manuscripts for several international journals. He has published more than 300 research papers of which over 179 are in International Journals. Dr Nair along with Mo Viji has published a book on Nanotechnology- role of nanoparticles in cancer therapy, by Lambart Academic Publishers and has also co-edited a book – ‘Radiosensitizers : a contemporary audit’ published by Narosa Publishing House, New Delhi. He has over 40 years of research and 25 years of postgraduate teaching experience. He was a recepient of Alexander Hollander Award from International Environmental Mutagen Society, a visting Professor at Osaka University, Japan Aug 1999- Nov. 1999 and at presen visiting professor in King Saud University, Riyad, Kingdom of Saudi Arabia. He .was invited speaker and chairman of scientific sessions in several international meetings in India and abroad. He was a member of Faculty of Science in MS University of Baroda and Board of studies in Biochemistry in University of Mumbai, also a Research guide for Ph.D. for M.G. University, Mumbai University, Manipal University and Meenalshi University.. Guided more than 100 dissertations at Masters level from several Universities in India and 16 Ph.D. theses from University of Mumbai and MG University and also coguided one Ph.D. from Manipal University. He was a Member Governing Body and Professor of Radiation Biology at Amala Cancer Research Centre, Thrissur, Kerala till recently. He is a life member of several Professional bodies (ISRB, ISSOL, EMSI, IARP,IABS, IACR, SCRAC etc) and Joint Secretary of National Society of Ethnopharmacology. During the last few years his research efforts were for finding nontoxic radioprotectors for human application and for developing methods to improve cancer therapy – both radiotherapy and chemotherapy. His research was focused on developing drugs, phytoceuticals, nutraceuticals and metal / metal oxide – nanoparticle-bound drugs for radioprotection in human situations particularly with respect to protection of normal tissues from deleterious consequences of radiation exposure during radiotherapy of tumours , developing drugs or treatment modalities to mitigate deleterious side effects such as systemic toxicities of chemotherapy and developing drugs employing nanotechnology for better and more efficient treatment of cancer employing magnetic particles for effective drug delivery.

1. Ffinding nontoxic radioprotectors for human application and for developing methods to improve cancer therapy – both radiotherapy and chemotherapy. 2. Developing drugs, phytoceuticals, nutraceuticals and metal / metal oxide – nanoparticle-bound drugs for radioprotection in human situations particularly with respect to protection of normal tissues from deleterious consequences of radiation exposure during radiotherapy of tumours , 3. Developing drugs or treatment modalities to mitigate deleterious side effects such as systemic toxicities of chemotherapy and 4. Developing drugs employing nanotechnology for better and more efficient treatment of cancer employing magnetic particles for effective drug delivery.